Matton, Anna https://orcid.org/0000-0002-7819-0495
Stephen, Ruth https://orcid.org/0000-0002-3380-9530
Daniilidou, Makrina https://orcid.org/0000-0002-5460-9802
Barbera, Mariagnese https://orcid.org/0000-0002-8983-1294
Alanko, Vilma https://orcid.org/0000-0001-9918-9429
Ballin, Marcel https://orcid.org/0000-0002-9638-7208
Ford, Jamie
Hemiö, Katri
Lehtisalo, Jenni https://orcid.org/0000-0002-8818-0848
Rocha, Sabsil López https://orcid.org/0009-0007-5435-6773
Mangialasche, Francesca https://orcid.org/0000-0002-2686-3926
Ngandu, Tiia https://orcid.org/0000-0002-3698-2021
Rosenberg, Anna https://orcid.org/0000-0003-1456-7991
Saadmaan, Gazi https://orcid.org/0000-0002-0925-7609
Udeh-Momoh, Chinedu https://orcid.org/0000-0002-7357-4692
Uusimäki, Kerttu https://orcid.org/0000-0002-2090-5291
Solomon, Alina https://orcid.org/0000-0002-7166-9903
Kivipelto, Miia https://orcid.org/0000-0003-0992-3875
Funding for this research was provided by:
European Union (EU) Joint Programme for Neurodegenerative Disease Research
EU Innovative Health Initiative Joint Undertaking
ERA PerMed Pattern‐Cog grant
European Research Council (804371)
Alzheimer's Drug Discovery Foundation
Alzheimer’s Disease Data Initiative
Davos Alzheimer's Collaborative
Gates Ventures
NordForsk
Alzheimerfonden
Region Stockholm ALF-medel
Center for Innovative Medicine
Stiftelsen Stockholms sjukhem
Forskningsrådet om Hälsa, Arbetsliv och Välfärd
Gun och Bertil Stohnes Stiftelse
Stiftelsen för Gamla Tjänarinnor
Triton Advisors
Juho Vainion Säätiö
Finnish Cultural Foundation
Yrjö Jahnssonin Säätiö
Karolinska Institute
Article History
Received: 20 December 2024
Accepted: 17 April 2025
First Online: 23 June 2025
Declarations
:
: Not applicable.
: Not applicable.
: M.Bal. is employed at the Swedish Medical Products Agency, SE-751 03 Uppsala, Sweden. The views expressed in this paper do not necessarily represent the views of this Government agency.